2025 ISV ANNUAL CONGRESS
ORAL PROGRAM
TUESDAY 28 OCTOBER 2025

08:00-10:00	**REGISTRATION**		
09:00-10:00	**WELCOME COFFEE**		
10:00-10:10	**OPENING SESSION** **WELCOME BY ISV PRESIDENT: Linda Klavinskis** **CO-CHAIR REMARKS: Ed Rybicki, Michael Schotsaert, Michelle Groome**		
10:10-10:40	**STANLEY PLOTKIN LECTURE: HIV Vaccines: Prospects for Their Use in Africa** **Linda-Gail Bekker,** *Desmond Tutu HIV Centre, University of Cape Town, South Africa*		
10:40-12:00	**PLENARY SESSION 1: Structure Based Vaccine Design**		
10:40-11:05	**AI-based engineering of stabilized glycoproteins to improve vaccine efficacy and manufacturability** **Hans Langedijk,** *ForgeBio, Netherlands*		
11:05-11:30	**Structure-Based Engineering of a Borrelia burgdorferi Vaccine Antigen Enhances Stability and Immunogenicity for Lyme Disease Prevention** **Kalvis Brangulis,** *Riga Stradins University, Latvia*		
11:30-11:45	**Harnessing Chaperone in Structure-based Vaccine Design: RNA-based Regulated Assembly of VLPs and NPs** **Baik-Lin Seong,** *Yonsei University, South Korea*		
11:45-12:00	**Structure-based vaccine design of viral hemagglutinin to induce broadly neutralizing responses against influenza A virus** **Nicholas Morano,** *Columbia University, USA*		
12:00-13:30	**LUNCH**		
12:30-13:30	**Canadian NRC Workshop on Specific New Technology Topics**		
13:30-15:00	**PLENARY SESSION 2: Systems Approaches to Next Generation Vaccines**		
13:30-13:55	**Systems Vaccinology** **Bali Pulendran,** *Stanford University, USA*		
13:55-14:20	**Systems Human Immunology: Immune Setpoint and Immune Health (RECORDING)** **John Tsang**, *Yale University, New Haven, USA*		
14:20-14:35	**Breadth and Durability of RTS,S/AS01E-Induced Humoral Correlates of Protection in Controlled Human Malaria Infection and Field Efficacy Trials** **Lenny Moise,** *SeromYx Systems, USA*		
14:35-14:50	**Deciphering Immune Response Dynamics to the M72/AS01E Tuberculosis Vaccine Using Systems Transcriptomics** **Taofeek Oluwaseun,** *Crescent University, Nigeria*		
15:00-15:30	**COFFEE BREAK**		
15:30-17:30	**CONCURRENT SESSION 1** **Next Generation Tools and Technologies for Vaccine Development**	**CONCURRENT SESSION 2** **Defending the Future: Vaccines, Emerging Threats, and One Health**	**CONCURRENT SESSION 3** **"Bright Sparks" in Vaccinology PhD student session**
15:30-15:55	**Advancing self-amplifying RNA as a vaccines platform** **Robin Shattock,** ***Imperial College London, United Kingdom***	**TITLE TBC** **Jacob Cramer,** ***Coalition for Epidemic Preparedness (CEPI)***	**The Mexican High-Resolution HLA Database And Its Use To Select And Validate T-Cell Epitopes For Vaccines** **Arturo Lian-Torres,** *National Autonomous University of Mexico, Mexico* *(15:30-15:40)*

15:55-16:20	**Targeting Antimicrobial Resistance (AMR) with Innovative Vaccines** **Michael Kowarick,** *Limmatech, Switzerland*	**Crimean-Congo Hemorrhagic Fever Virus (CCHFV); From the lab bench to clinical trial** **Ali Mirazimi,** *Karolinska Institute, Sweden*	**Ionisable Lipids Synthesised from Biorenewable Waste as Delivery Vehicles and Adjuvants in mRNA Vaccines** **Dylan Kairuz,** *University of the Witwatersrand, South Africa* *(15:40-15:50)*
16:20-16:35	**Toward the Development of a Pan-Beta-Coronavirus Vaccine** **Jeffrey Ulmer,** *TechImmune LLC, USA*	**Safety, Tolerability and Immunogenicity of a First In Africa Vaccine Against Lassa Fever Virus, Synthetic Dna-Based Ino-4500, In a Phase 1b Clinical Trial In Healthy Ghanaian Adults** **Kwadwo Koram,** *Noguchi Memorial Institute for Medical Research/University of Ghana, Ghana*	**Development of Stable Plant-Based Nanoparticle-Encapsidated mRNA Vaccines** **Natalie Nel,** *University of Cape Town, South Africa* *(15:50-16:00)*
16:35-16:50	**Vaccines on Demand Are Within Reach: Validating Immunoinformatics-Driven Vaccine Design Through Preclinical and Clinical Applications** **Anne De Groot,** *EpiVax Inc., USA*	**mRNA Vaccines Against Rift Valley Fever Virus and Marburg Virus** **Alexander Bukreyev,** *University of Texas Medical Branch at Galveston, USA*	**Immunogenicity of Self-Amplifying RNA Vaccines Against Hepatitis B Virus** **Nazia Samudh,** *University of the Witwatersrand, South Africa* *(16:00-16:10)*
16:50-17:05	**From Blood To Bench: Broad-Spectrum Bacterial Vaccine Targets Via Functional Antibody Discovery** **Fadil Bidmos,** *Imperial College London, United Kingdom*	**Cross Reactivity Among Coronaviruses and The Development of Pan-Sarbecovirus and Pan-Betacoronavirus Vaccines Using a Protein Subunit Platform** **Alyson Kelvin,** *University of Calgary Faculty of Veterinary Medicine, Canada*	**Using Single Cell RNA Sequencing to Assess Immunological Responses in Quails Injected with Porcine Circovirus-Like Particles** **Lekita Singh,** *University of Cape Town, South Africa* *(16:10-16:20)*
17:05-17:20	**Development of a Complement-Dependent mRNA Vaccine Candidate for Gonorrhoea for LMICs Enabled by AI-Powered Antigen Selection** **Frances Lees,** *Afrigen Biologics, South Africa*	**Targeted Ebola Vaccination Among Survivor Networks in the Democratic Republic of the Congo: A Feasibility Campaign Beyond Ebola Outbreak Context** **Trésor Zola Matuvanga,** *Université de Kinshasa, Congo-Kinshasa*	**Low Vitamin B12 Levels and Anaemia Are Associated with Impaired Pneumococcal Vaccine Responses in Young Kenyan Children** **Kelvin Mokaya Abuga,** *KEMRI-Wellcome Trust Research Programme* *(16:20-16:30)*
17:20-17:35	**A FIH Dose-Escalation Trial of the Safety and Pharmacokinetics of Anti-SARS-CoV-2 DNA-Encoded Monoclonal Antibodies (DMAb) Formulated for Delivery by CELLECTRA in Healthy Adults** **David Weiner,** *Wistar Institute, USA*	**Evaluation Of the Safety and Efficacy of a Crimean-Congo Hemorrhagic Fever Vaccine – A One Health Approach** **Catherine Olal,** *Univesrity of Texas Medical Branch at Galveston, USA*	**Superior Protection and Prevention of Transmission Upon Influenza Infection By Adjuvanted Mucosal Vaccination in the Guinea Pig Influenza Model** **Vivian Yan,** *Icahn School of Medicine at Mount Sinai, USA* *(16:30-16:40)*
			Enhanced Mucosal SARS-CoV-2 Immunity After Heterologous Intramuscular mRNA Prime/Intranasal Protein Boost Vaccination with a Combination Adjuvant

			Gabriel Laghlali, *Icahn School of Medicine at Mount Sinai, USA* *(16:40-16:50)*
			Seroprevalence, Associated Risk Factors, and Molecular Detection of Brucella spp. in Cattle, Sheep, Goats and Humans in Mvomero District, Morogoro, Tanzania **Emmanuel Lita** *Sokoine University of Agriculture, Tanzania* *(16:50-17:00)*
			Evaluation of Highly Conserved Burkholderia pseudomallei Proteins as pan-Burkholderia Vaccine Antigen Candidates **Alexander Badten,** *University of Texas Medical Branch, USA* *(17:00-17:10)*
			Gut Microbiota Serve as Biomarkers to Predict Antibody Response to the Domestic Herpes Zoster Live Attenuated Vaccine in China **Simin Li,** *The Jiangsu Provincial Center for Disease Control and Prevention, China* *(17:10-17:20)*
			Development of Crimean-Congo Haemorrhagic Fever Chadox2-Vectored Vaccines with First-In-Human, Phase 1 Clinical Trial Progression **Jack Saunders,** *University of Oxford, United Kingdom* *(17:20-17:30)*
17:35-19:00	**POSTER SESSION 1**		
17:35-20:00	**WELCOME RECEPTION**		

WEDNESDAY 29 OCTOBER 2025			
08:00-08:30	**MORNING COFFEE**		
08:30-09:00	**KEYNOTE LECTURE: Nucleoside-modified mRNA-LNP therapeutics** **Drew Weisman,** *UPenn, USA*		
09:00-10:35	**PLENARY SESSION 3: Climate, Environment, and Vaccination: Responding to a Changing World**		
09:00-09:25	**Using genomics to characterize and respond to climate amplified disease and epidemics** **Tulio de Oliveira,** *University of Stellenbosch, South Africa*		
09:25-09:50	**Dengue: global epidemiology and strategies for prevention and control** **Fernanda Boulos,** *Butatan Institute, Brazil*		
09:50-10:05	A Multi-Antigen DNA Vaccine Induces Mucosal Immune Protection From Valley Fever, A Respiratory Fungal Disease that is Spreading Due to Climate Change **Deborah Fuller,** *University of Washington, USA*		
10:05-10:20	A Universal Cross-Stage, Cross-Species Malaria CD8 T cell Vaccine based on HLA-E Presentation **Gabriela Samayoa Reyes,** *Vaccine and Gene Therapy Institute, USA*		
10:20-10:35	Tracking the Spread of Antimalarial Drug Resistance: Molecular Markers Analysis in Central and South-Eastern Senegal, 2019 **Mamadou Yade,** *International Center for Research and Training on Applied Genomics and Health Surveillance (CIGASS), Mali*		
10:35-11:00	**COFFEE BREAK**		
11:00-12:35	**CONCURRENT SESSION 4** **MPOX AND OTHER VECTORED VACCINES**	**CONCURRENT SESSION 5** **VACCINES AND IMMUNOTHERAPEUTICS AGAINST MUCOSAL PATHOGENS**	**CONCURRENT SESSION 6** **"Bright Sparks" in Vaccinology ECR session**
11:00-11:25	**The Emergence of Mpox Clade Ib, an accident waiting to happen** **Laurens Liesenborghs**, *Institute for Tropical Medicine, Antwerp, Belgium*	**Shigella Vaccines – Advancing Innovation to Combat a Global Health Threat** **Francesca Micoli,** *GSK, Italy*	**A Phase III Randomized Controlled Multi-Centre Trial Evaluating the Efficacy of the R21/Matrix-M Vaccine in African Children Against Clinical Malaria** **Angela Gwakisa,** Ifakara Health Institute, Tanzania *(11:00-11:10)*
11:25-11:50	**The Role of MVA-BN in Mpox Management: Current Data and Future Directions** **Melvin Sanicas**, *Bavarian Nordic, Switzerland*	**Humoral and mucosal immunity, and retention of attenuated phenotype: results of a phase 1 study of novel type 1 and 3 OPVs** **Chris Gast**, *PATH, USA*	**Oral Immunization with Filoviral-Like Particles Elicits Ebola-Specific Humoral and Cellular Immune Responses and Confers Protection from Ebola Challenge In Mice** **Juan Garcia-Bernalt Diego,** *Centro de investigación Hospital Universitario 12 de Octubre, Spain* *(11:10-11:20)*
11:50-12:05	**Genetic Diversity and Population Structure of Mpox Virus In Africa: Identifying Key Targets For Vaccine Development** **Abubakar Woziri,** *Ahmadu Bello University, Nigeria*	**A Potent Monoclonal Antibody Against Gonococcal Lipooligosaccharide with Enhanced Effector Function and Half-Life** **Davinder Gill,** *StiRx Inc, USA*	**Intranasal Spike Protein with Mucosal Combination Adjuvant: Potential for Mucosal Booster Vaccination After Intramuscular mRNA Vaccine Against SARS-CoV-2** **Seokchan Park,** *Icahn School of Medicine at Mount Sinai, USA* *(11:20-11:30)*
12:05-12:20	**Utilizing the VSV Vector Approach for Emerging Infections Disease Vaccine Development** **Marija Zaric,**	**Swab And Spray: A Proposal for Future Precision Immunization Against Respiratory Infections Through Infection Risk**	**Comparative Analysis of the HIV-1 Subclade C Reservoir Localization and Cellular Function in Pediatric and Adult Tonsillar Tissues**

	IAVI, United Kingdom	**Assessment and Nasal Vaccination** **Ling Chen,** *Guangzhou Medical University, China*	**Faiaz Shaik Abdool** *Africa Health Research Institute, South Africa* *(11:30-11:40)*
12:20-12:35	**A New Single-Virus MMR Vaccine: Measles-Based Vector Expressing Rubella and Mumps Antigens** **Phanramphoei Frantz** *Institut Pasteur, France*	**Engineered Design of Mucus Penetration Nanoparticles for Inhalable Vaccines** **Bingbing Sun,** *Dalian University of Technology, China*	**Empty Vector Plasmid DNA in Lipid Nanoparticles is a Potent Adjuvant for Recombinant Protein Vaccines** **Nicholas Tursi,** *The Wistar Institute, USA* *(11:40-11:50)*
			M72/AS01E Vaccination Boosts Polyfunctional Effector Memory CD4+ T Cell Populations That May Serve as Immune Correlates of Protection **Sharon Khuzwayo,** *Cape Town HVTN Immunology, South Africa* *(11:50-12:00)*
			Durability and Functional Profile of T Cell Responses to SARS-CoV-2 After Multiple Vaccinations in People Living with HIV **Maxine Hoft,** *University of Cape Town, South Africa* *(12:00-12:10)*
			Development of a Genotype-Matched Newcastle Disease DNA Vaccine Candidate Adjuvanted with IL-28b for the Control of Targeted Velogenic Strains of Newcastle Disease Virus in Africa **Charlie Amoia,** *SACIDS Foundation for One Health, Tanzania* *(12:10-12:20)* _____ *ECR Slot*
12:35-14:00	**LUNCH**		
13:00-14:00	**ROUNDTABLE: The Future Vaccine Manufacturing Hub; Roundable on RNA Vaccines for LMIC**		
13:00-14:00	**PANEL DISCUSSION FOR ECR'S: Vaccines we have not Considered Yet – Vaccines for Space Travel**		
14:00-15:30	**POSTER SESSION 2**		
14:30-15:30	**ISV ANNUAL GENERAL MEETING**		
15:30-16:00	**COFFEE BREAK**		
16:00-17:35	**PLENARY SESSION 4: Maternal and Newborn Vaccination in Preventing Disease**		
16:00-16:25	**Opportunities and challenges in prevention of respiratory syncytial virus in infants through maternal immunization** **Shabir Madhi,** *University of the Witwatersrand, South Africa*		
16:25-16:50	**Group B Streptococcus, pathway to a vaccine** **Kirsty Le Doare**, *University of London/Makerere University Johns Hopkins University, UK/Uganda*		
16:50-17:05	**How Can We Unlock Inflationary CMV-Specific T Cell Immunity During Pregnancy in the Design of a Maternal Vaccine Against CMV** **Brandon Paarwater,** *Stellenbosch University, South Africa*		

17:05-17:20	**Embarking on a Path of Clinical Development of A Haemophilus Influenzae Type A Vaccine** **Joanne Langley,** *Dalhousie University, Canada*
17:20-17:35	**Long-Term Immunogenicity of a Single Dose Compared with a Two-Dose Primary Series Followed by a Booster Dose Of 10- Or 13-Valent Pneumococcal Conjugate Vaccines In South African Children Up To 5 Years Of Age: An Open-Label, Randomised, Non-Inferiority Trial** **Daniel Kapelus,** *University of the Witwatersrand, South Africa*
18:00	**PICK UP FOR GALA DINNER**

THURSDAY 30 OCTOBER 2025			
08:00-08:30	**MORNING COFFEE**		
08:30-09:00	**KEYNOTE LECTURE: Novel TB vaccines: is control of the global epidemic on the horizon?** **Willem Hanekom**, *Africa Health Research Institute, South Africa*		
09:00-10:35	**PLENARY SESSION 5: Progress in Therapeutic Cancer Vaccines**		
09:00-09:25	**RNA Vaccines for Pancreatic Cancer** **Vinod Balachandran**, *Memorial Sloan Kettering Cancer Center, USA*		
09:25-09:50	**NanoEngineering gone viral: plant virus-based immunotherapy** **Nicole Steinmetz,** *University of California, USA*		
09:50-10:05	**An mRNA Cancer Vaccine Encoding a DC-Targeting Peptide and Flagellin Induces Potent Antitumor Responses in a Murine Model** **Joon Haeng Rhee,** *Chonnam National University, South Korea*		
10:05-10:20	**Novel Nanokine-Tm Technologies to Control Regulatory Immunity for New Immunotherapy Treatments for Infectious Disease and Oncology** **Ursula Gompels,** *Virothera Ltd, United Kingdom*		
10:20-10:35	**Immunotherapy, INO-3107, is Well-Tolerated, Effective, and Elicits an Antigen-Specific T-cell Response in Adults with HPV-6 & 11 Recurrent Respiratory Papillomatosis** **Jacqueline Shea,** *Inovio Pharmaceuticals, Inc., USA*		
10:35-10:55	**COFFEE BREAK**		
11:00-12:45	**CONCURRENT SESSION 7** **What's new in HIV vaccine development**	**CONCURRENT SESSION 8** **Unlocking immunity: Mechanistic insights driving Next Gen Vaccine design**	**CONCURRENT SESSION 9** **Public Health Approaches in Vaccinology**
10:55-11:20	**Targeting HIV broadly neutralizing antibody precursors in humans with atomic precision** **Rogier Sanders**, *University of Amsterdam, The Netherlands*	**Focusing on conserved immunogenic regions results in broad breadth of Betacoronavirus virus T cell recognition** **Alba Griffoni,** *La Jolla Institute, USA*	**Can vaccines move cholera ahead of the epidemic curve?** **Lucille Blumberg,** *Nat. Inst. for Communicable Diseases, South Africa*
11:20-11:45	**HIV vaccine design – keeping up with the Envelope** **Penny Moore**, *University of Witwatersrand, South Africa*	**Interferons and inflammasomes as mediators of adjuvant induced immunity** **Ed Lavelle,** *Trinity College Dublin, Ireland*	**Harnessing respiratory virus vaccines for public health impact** **Cheryl Cohen,** *University of Witwatersrand, South Africa*
11:45-12:00	**Engineering Cytoplasmic Domains of Stabilized mRNA Env Immunogens Enhances Neutralizing Response** **Edward Kreider,** *University of Pennsylvania School of Medicine, USA*	**Differential Immune Responses to a Trimeric RBD-Based SARS-CoV-2 Vaccine Shaped by Licensed Types of Adjuvants** **Han Zibo,** *National Vaccine and Serum Institute, China*	**Neutralizing Antibody Titers Predict Protection from Virus Transmission in a Cohort of Household Members with Documented Exposure to SARS-CoV-2** **Luka Cicin-Sain,** *Helmholtz Centre for Infection Research, Germany*
12:00-12:15	**Heterologous Immunization with Improved Hiv-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After Shiv Challenge** **Rosamund Chapman,** *University of Cape Town, South Africa*	**Tolerogenic mRNA-Lipid Nanoparticle Vaccines for Autoimmune Disease** **Jilian Melamed,** *University of Pennsylvania, USA*	**Factors Influencing Maternal Vaccine Uptake Among Adults in Johannesburg, South Africa: A Qualitative Study** **Mulalo Mashamba,** *Vaccines and Infectious Diseases Analytics Research Unit, South Africa*

12:15-12:30	**Concurrent Schistosoma Mansoni Infection Suppresses Induction Of HIV-1 Neutralizing Antibodies in a Dna/Mva/Gp140 Env Vaccine Regimen in Rhesus Macaques** **Gerald Chege,** *South African Medical Research Council, South Africa*	**Convergent and Clonotype-Enriched Mutations Drive Affinity Maturation of a Public Antibody** **Vishal Rao,** *Icahn School of Medicine at Mount Sinai, USA*	**Perception of Disease Severity Drives Willingness for Cholera Vaccine Uptake: Evidence From a Covid-19 Surveillance Cohort** **Andrew Musyoki,** *Sefako Makgatho Health Sciences University,* *South Africa*
12:30-12:45	**Stabilized HIV Envelope Trimer DNA/LION Vaccines Induce Autologous Tier 2 Neutralizing Antibodies and Strong Cytotoxic CD8 Cells in Macaques** **Margherita Rosati,** *NIH/NCI, USA*	**Harnessing The Potential of mRNA Vaccines Against Hepatitis C Virus** **Branka Grubor-Bauk,** *University of Adelaide, Australia*	**Mpox Vaccination in Africa: One Year On - Lessons and Milestones From the Continental Response** **Charles Ibeneme,** *Africa Centers for Disease Control and Prevention, Zambia*
12:45-14:00	**LUNCH**		
13:00-14:00	**CAREER DEVELOPMENT WORKSHOP**		
14:00-14:30	**AWARD CEREMONY**		
14:30-14:55	**ISV PAPER OF THE YEAR:** **Development of a quadrivalent mRNA-lipid nanoparticle vaccine to elicit cross-reactive immune responses against diverse Orthopoxviruses** **Alec Freyn, *Moderna, USA***		
14:55-16:10	**PLENARY SESSION 6:** **Cutting-Edge Innovations in Vaccine Manufacturing: The Future of Scalable Production**		
14:55-15:20	**Manufacturing effective vaccines using modern technology'** **Indresh Srivastava,** *Novavax, Maryland, USA*		
15:20-15:45	**Advancing sustainable local vaccine manufacturing through end-to-end project support** **Nicaise Ndembi,** *DDG, IVI, Africa*		
15:45-16:10	**Development of bacterial vaccines and strategic collaboration for regional vaccine manufacturing.** **Shin-Hee Jun,** *EuBiologics, South Korea*		
16:10-16:30	**CLOSING SESSION** **2025 CONFERENCE REFLECTIONS,** **ED RYBICKI, UNIVERSITY OF CAPE TOWN** **INTRODUCTION TO 2026 ISV CONGRESS (ANTWERP, BELGIUM)** **MICHAEL SCHOTSAERT, ICAHN SCHOOL OF MEDICINE, MOUNT SINAI**		